Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Abstract Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We pres...

Full description

Saved in:
Bibliographic Details
Published inCase reports in oncology Vol. 15; no. 2; pp. 720 - 725
Main Authors Koster, Kira-Lee, Appenzeller, Christina, Lauber, Arno, Früh, Martin, Schmid, Sabine
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 26.08.2022
Karger Publishers
Subjects
Brain cancer
Cancer
Case Report
Case reports
Clinical trials
Conflicts of interest
Disease control
Drug resistance
kras inhibition
kras-mutated nsclc
Lung cancer
Metastasis
Mutation
nsclc with active brain metastases
Patients
Radiation therapy
Remission (Medicine)
Signal transduction
KRAS-mutated NSCLC
NSCLC with active brain metastases
KRAS inhibition
Online AccessGet full text

Cover

More Information
Summary:Abstract Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with KRAS G12C-mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in KRAS G12C-mutated NSCLC.
ISSN:1662-6575
1662-6575
DOI:10.1159/000525341